On Friday, Kevenue, the maker of Tylenol, saw its stocks drop more than 10% after the Wall Street Journal reported that Health and Human Services Secretary Robert F. Kennedy plans to release a federal report connecting prenatal use of Tylenol to autism. As Kennedy and his appointed vaccine panel continue to erode vaccine recommendations, many… The post Vaccine makers’ stocks continue to spiral as the segment faces fresh pressures appeared first on Drug Discovery and Development.
